Glucotrack, Inc. announced that it has successfully completed a second long-term preclinical study for its Continuous Blood Glucose Monitor (CBGM). This study further validates the CBGM?s sustained accuracy and performance with a Mean Absolute Relative Difference (MARD) of 4.7% at Day 90, which is considered highly accurate for a continuous glucose monitor. MARD is a key metric used to assess the accuracy of glucose monitoring devices, measuring the average difference between the CBGM device?s measurement and a reference measurement, most often obtained via capillary blood glucose.

Lower values indicate better performance. Glucotrack?s CBGM measures glucose in the blood, without the lag time associated with subcutaneous sensors that measure glucose in interstitial fluid. The ability to directly measure blood glucose in real time and on a continuous basis enables a less burdensome approach to glucose monitoring for extended periods of time.

The 90-day preclinical study, which included a larger number of animal subjects and a longer duration than the initial 60-day study announced earlier this year, further validates the CBGM?s sustained accuracy and performance. The study incorporated periodic glucose tolerance testing to compare the performance of the Glucotrack CBGM against both a commercially available blood glucose monitor and a subcutaneous continuous glucose monitor. The study was completed with no significant adverse effects.

Glucotrack previously announced that it had completed preclinical animal testing in an acute setting and had initiated a long-term animal study to assess sustained glucose monitoring performance. The CBGM prototypes used in this study were manufactured using refined production techniques that bring the device closer to the commercially desired product. The Company plans to initiate human clinical trials later this year.